Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action
- 1 January 2012
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 142 (1), 44-48
- https://doi.org/10.1016/j.clim.2011.02.017
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Dimethylfumarate for psoriasis: more than a dietary curiosityTrends in Molecular Medicine, 2005
- Pharmacokinetics of oral fumarates in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid estersBiopharmaceutics & Drug Disposition, 2003
- The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cellsBritish Journal of Dermatology, 2001
- Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic useBritish Journal of Dermatology, 1999
- Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre studyBritish Journal of Dermatology, 1998
- Antipsoriatic effect of fumaric acid derivativesJournal of the American Academy of Dermatology, 1994
- Effects of Monomethylfumarate on Human GranulocytesJournal of Investigative Dermatology, 1993
- Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatmentJournal of the American Academy of Dermatology, 1992